RT Book, Section
A1 Trevor, Anthony J.
A1 Katzung, Bertram G.
A1 Kruidering-Hall, Marieke M.
A1 Masters, Susan B.
SR Print(0)
ID 56983976
T1 Chapter 47. Antimycobacterial Drugs
T2 Katzung & Trevor's Pharmacology: Examination & Board Review, 10e
YR 2013
FD 2013
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-178923-3
LK accesspharmacy.mhmedical.com/content.aspx?aid=56983976
RD 2024/04/20
AB The  chemotherapy  of  infections  caused  by  Mycobacterium  tuberculosis,  M  leprae,  and  M  avium-intracellulare  is  complicated  by  numerous  factors,  including  (1)  limited  information  about  the  mechanisms  of  antimycobacterial  drug  actions;  (2)  the  development  of  resistance;  (3)  the  intracellular  location  of  mycobacteria;  (4)  the  chronic  nature  of  mycobacterial  disease,  which  requires  protracted  drug  treatment  and  is  associated  with  drug  toxicities;  and  (5)  patient  compliance.  Chemotherapy  of  mycobacterial  infections  almost  always  involves  the  use  of  drug  combinations  to  delay  the  emergence  of  resistance  and  to  enhance  antimycobacterial  efficacy.